CA-DEGREED
15.6.2022 14:06:09 CEST | Business Wire | Press release
Degreed, a pioneer in learning experience for eight million users, today shared the results of a commissioned Total Economic ImpactTM (TEI) study of its Learning Experience Platform (LXP). The study, conducted by Forrester Consulting found that organizations using Degreed’s LXP experienced faster time-to-productivity for new employees, democratization of learning across the workforce, improved upskilling, and lower learning content costs. The potential total return-on-investment calculated in the study was 312%, with a net present value (NPV) of $4.69M and payback in under six months. Read the full study here .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005110/en/
“Our customers choose Degreed alongside their LMSs and HCM systems to build the skills their people need faster and more efficiently. We believe this Total Economic ImpactTM study highlights how Degreed’s more open, collaborative learning experience can create value at every stage of the employee lifecycle — from faster new hire onboarding to more efficient upskilling and lower turnover in key roles, not to mention reduced content spend and higher productivity for L&D teams,” said Todd Tauber, SVP Strategy at Degreed.
The study found organizations using Degreed had a 20% faster time-to-productivity for new employees due to a more consistent onboarding process, centered around high quality content and easily navigated learning pathways.
According to the study, “Interviewees’ organizations used Degreed to upskill employees and improve their organizations’ performance in a number of areas, including customer satisfaction and retention, data storage and analysis, product support, diversity and inclusion, leadership and management, and technology changes.”
One professional services organization was able to make onboarding more relevant and timely for new starters, where previously it depended on live instructors at synchronous training sessions, which delayed onboarding timelines and made the experience inconsistent.
Another customer commented on the benefits of the LXP’s open ecosystem, stating, “Degreed is the primary learning interface for us and it caters to the diverse needs of our employees, as well as our organization. With Degreed, we've achieved targeted and business-focused skill development.”
The improved upskilling of current employees across all respondents was 35% for employees and 25% for trainers because of the single gateway for all learning that Degreed provides. The study additionally found that Degreed led to better retention in key roles, decreasing from 10% to 2%, particularly in leadership positions and those who regularly deal with new challenges.
There were additional unquantified benefits that were identified by the study including bringing a social, consumer-grade learning experience to corporate learning, leading to higher levels of engagement, and the democratization of learning, particularly for frontline workers, those in new regions, and employees speaking different languages.
Interviewees also said that Degreed was one of their organization’s core technologies that provided the agility needed to successfully operate through remote work.
To read the full study, click here .
Degreed is hosting a webinar featuring Forrester to dive further into the details of the study, click here to register .
Editor’s notes
TEI Framework And Methodology
From the information provided in the interviews, Forrester constructed a Total Economic ImpactTM framework for those organizations considering an investment in Degreed.
The objective of the framework is to identify the cost, benefit, flexibility, and risk factors that affect the investment decision. Forrester took a multistep approach to evaluate the impact that Degreed can have on an organization.
About Degreed
Degreed empowers growth and innovation through lifelong learning. As a changemaker on a global scale, we serve more than 100 of the Global 2000 and one in three Fortune 50 companies, sparking a culture of learning across the enterprise. In one fluid experience, we help you identify the skills you have and build the skills you need—through individual, collaborative and experiential modes of learning—to drive personal career growth and business results. Founded in 2012, Degreed is translated into 28 languages with users spanning more than 200 countries.
Learn more about Degreed: Website | YouTube | LinkedIn | Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005110/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
